WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced the completion of its previously disclosed analysis of QTc prolongation data related to a Phase 1 dose escalation trial with ARQ 171, a second generation product in its E2F-1 DNA damage response cancer therapy program. Based on the confirmation of QTc prolongation associated with ARQ 171, the Company does not plan to pursue further clinical testing with this compound.
